Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.25 USD
Change Today +0.0048 / 1.98%
Volume 388.3K
NSPH On Other Exchanges
NSPH is not on other exchanges.
As of 5:20 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

nanosphere inc (NSPH) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/9/14 - $2.28
52 Week Low
01/26/15 - $0.22
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NANOSPHERE INC (NSPH)

Related News

No related news articles were found.

nanosphere inc (NSPH) Related Businessweek News

No Related Businessweek News Found

nanosphere inc (NSPH) Details

Nanosphere, Inc. develops, manufactures, and markets molecular diagnostic tests that can lead to earlier disease detection, optimal patient treatment, and enhanced healthcare economics. It offers a molecular diagnostics platform, Verigene System platform that enables clinicians to identify and treat the bacteria and viruses for complex, costly, and deadly infectious diseases. The Verigene System includes a bench-top molecular diagnostics workstation for genomic and protein testing. The Verigene System is used for testing infectious disease assays, human and pharmacogenetic assays, and ultra-sensitive protein assays. The company focuses on serving hospital-based laboratories and academic research institutions in the United States. Nanosphere, Inc. was founded in 1998 and is headquartered in Northbrook, Illinois.

169 Employees
Last Reported Date: 02/11/15
Founded in 1998

nanosphere inc (NSPH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $330.0K
Chief Strategy Officer
Total Annual Compensation: $211.0K
Compensation as of Fiscal Year 2013.

nanosphere inc (NSPH) Key Developments

Nanosphere, Inc. Announces Clinical Study Results of Verigene Gram-Positive Blood Culture Test

Nanosphere, Inc. announced publication of a study that demonstrates the clinical and economic impact of implementing rapid sepsis diagnostic testing with the Company's FDA-cleared Verigene Gram-Positive Blood Culture Test (BC-GP) in combination with Antimicrobial Stewardship Team (AST) intervention. This multi-center, pre-post study was conducted at the five hospitals that compose Scripps Health in San Diego, California and published in the peer-reviewed journal Pharmacotherapy. The statistically significant findings included a 25.7 hour reduction in time to targeted therapy (61.1 versus 35.4 hours), a 1.9 day median reduction in length of stay (9.1 versus 7.2 days) and $7,240 reduction in median hospital costs per patient ($17,530 versus $10,290). The manuscript, published under the title "Outcomes of Rapid Identification for Gram Positive Bacteremia in Combination with Antibiotic Stewardship at a Community Based Hospital System," was composed by Maggix Box, PharmD, Eva Sullivan, PharmD, Kristine Ortwine, MPH, Mark Parmenter, PharmD, Michael Quigley, MD, Louise Aguilar-Higgins, CLS, MT, Cynthia MacIntosh, CLS, Kristina Goerke, CLS, and Rachael Lim, PharmD.

Nanosphere Announces Verigene System Positioned to Provide Rapid Diagnosis of Outbreaks of CRE "Superbugs"

Nanosphere, Inc. announced that it offers the Verigene® Gram-Negative Blood Culture Test (BC-GN), approved by the FDA in June 2014 as the first and only FDA-cleared test that rapidly identifies the five carbapenem resistance genes most commonly associated with carbapenem-resistant Enterobacteriaceae (CRE). Three recent outbreaks of CRE, also known as "superbugs," are shining light on the dangers associated with multi-drug-resistant infections. Across three U.S. medical centers, the outbreaks led to two deaths and affected nearly 300 patients overall. While considered rare in the U.S., the U.S. Centers for Disease Control and Prevention (CDC) notes that 48 states have had confirmed cases of CRE infections. The Verigene® Gram-Negative Blood Culture Test (BC-GN) detects CRE days faster than current testing methods, which Nanosphere believes may enable clinicians to optimize treatment of patients.

Nanosphere, Inc. Proposes Amendments to the Company's Charter

Nanosphere, Inc. proposed amendments to the company's charter to increase the authorized shares of its common stock from 150 million to 250 million shares.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NSPH:US $0.25 USD +0.0048

NSPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GenMark Diagnostics Inc $13.09 USD +0.04
Great Basin Scientific Inc $1.95 USD -0.02
Luminex Corp $15.78 USD -0.17
Meridian Bioscience Inc $19.13 USD -0.08
Quidel Corp $26.52 USD -0.38
View Industry Companies

Industry Analysis


Industry Average

Valuation NSPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOSPHERE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at